Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA for up to ~3.5 Years
Posted on 192 Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis of three controlled phase 3 (PALISADE 1, RAMSES, ARTEMIS 3, ARC008, ARC011) trials of PALFORZIA ® [Peanut ( Arachis hypogaea) Allergen Powder-dnfp]. These data will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting held February 26 – March 1, 2021. In patients with p...
Source: financialbuzz.com